Western Equine Encephalitis - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 26 pages report, published by Global Markets Direct

Keywords : Western Equine Encephalitis Therapeutic Products under Development, Key Players in Western Equine Encephalitis Therapeutics, Western Equine Encephalitis Pipeline Overview, Western Equine Encephalitis Pipeline, Western Equine Encephalitis Pipeline Assessment

Report ThumbnailJune-2017
Western Equine Encephalitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2017, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape.

Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Western Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Western Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Western Equine Encephalitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Western Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Western Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Western Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Western Equine Encephalitis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Western Equine Encephalitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Western Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Western Equine Encephalitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development for Western Equine Encephalitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Western Equine Encephalitis - Pipeline by Akshaya Bio Inc, H1 2017
  • Western Equine Encephalitis - Pipeline by Altravax Inc, H1 2017
  • Western Equine Encephalitis - Pipeline by EpiVax Inc, H1 2017
  • Western Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H1 2017
  • Western Equine Encephalitis - Dormant Projects, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Western Equine Encephalitis - Overview
  • Western Equine Encephalitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Western Equine Encephalitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Western Equine Encephalitis - Companies Involved in Therapeutics Development
  • Akshaya Bio Inc
  • Altravax Inc
  • EpiVax Inc
  • Profectus BioSciences Inc
  • Western Equine Encephalitis - Drug Profiles
  • equine encephalitis (trivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • equine encephalitis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • equine encephalitis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for Western Equine Encephalitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • western equine encephalitis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Westrern Equine Encephalitis Virus Vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Western Equine Encephalitis - Dormant Projects
  • Western Equine Encephalitis - Product Development Milestones
  • Featured News & Press Releases
  • Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectWestern Equine Encephalitis - Pipeline Review, H1 2017Product ThumbnailWestern Equine Encephalitis - Pipeline Review, H1 2017, Industry ReportProduct #: 828997
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved